Endometabolic DrugNews

Do you need to know what is happening in the drugs and R&D pipeline for:

• Acid-base regulation and disorders?
• Adrenal disorders?
• Amyloidosis?
• Carcinoid tumours?
• Diabetes mellitus and disorders of carbohydrate metabolism?
• Fluid and electrolyte metabolism?
• Lipid disorders?
• Multiple endocrine neoplasia?
• Obesity?
• Pituitary disorders?
• Polyglandular deficiency syndromes?
• Porphyrias?
• Thyroid disorders?

Many of these disorders and conditions are widespread in society. Patient populations for specific diseases are often low, and several have no cure or really effective symptomatic treatment. Opportunities exist for effective and safe high-return low-volume products. For pharmaceutical company executives and researchers, staying in touch with the latest twists and turns involving companies and research can be a time-consuming exercise. That is why this new, regularly updated online information service is essential.

Endometabolic Drug News provides:

• The latest company, product and research news related to all types of endometabolic disorders
• An easy-to-use interface that immediately takes you to the most recently updated information
• An extensive archive of over 5,100 articles which makes the service a valuable tracking and research tool
• A fast and effective search facility allowing you to identify information relevant to you
• Daily or weekly email alerts that will ensure you know when new information is added
• An RSS feed facility

Every day, Espicom’s researchers and editors

• Track the companies and research organisations that are shaping the industry
• Report the latest developments in current and up and coming products
• Monitor results from major conferences and meetings

These days we all suffer from information overload. By focusing specifically on this key sector, the newly launched Endometabolic Drug News service will deliver the information you need in a timely, flexible and convenient format.

Start your subscription today!

Endometabolic Drug News is available exclusively by subscription and provides:

• 24/7 single-user access for one year
• Regularly updated news and research archive – all full text
• An easy-to-use interface and full search function
• Daily/weekly email alerts

Cost-effective multi-user distribution deals means the service can be used widely by colleagues in your organisation – contact direct_sales@espicom.com for details, alternatively you can use our contact us page.